Supplementary Table 1 Clause Samples
Supplementary Table 1. Distribution of adjuvant chemotherapy, endocrine therapy, and trastuzumab, according to patient and tumor characteristics Characteristics Chemotherapy No. (%) Endocrine therapy No. (%) Trastuzumab (with chemotherapy)* No. (%) * Patients diagnosed between 2003-2004 were excluded, since recommendation for HER2 testing and the use of trastuzumab was implemented from 2005 onwards 5‐year 95% CI 10‐year 95% CI Characteristics No. %